Accuray (ARAY) vs Cerenome (CNSY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Accuray (ARAY) has outperformed Cerenome (CNSY) over the past year, gaining 97.6% versus a loss of 95.2%. Over five years, ARAY leads with a -59.5% price change compared with -99.9% for CNSY. Accuray is the larger company by market cap ($6.2 million vs $6.2 million), about 1.0 times the size, while Cerenome is growing revenue faster (-10.5% vs -12.3%).
Accuray converts more of its revenue into profit, with a net margin of -12.2% versus -429.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARAY | CNSY |
|---|---|---|
| Share price | $2.08 | $0.6301 |
| Market cap | $6.22M | $6.16M |
| 1-day change | -2.12% | -10.29% |
| YTD return | +153.05% | -95.06% |
| 1-year return | +97.62% | -95.24% |
| 5-year return | -59.47% | -99.89% |
| EPS (TTM) | $-5.60 | $-3.50 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $401.95M | $5.21M |
| Revenue growth (YoY) | -12.34% | -10.49% |
| Net income (latest FY) | $-49.19M | $-22.39M |
| Gross margin | 27.73% | — |
| Operating margin | -6.58% | -293.46% |
| Net margin | -12.24% | -429.43% |
| 52-week high | $45.20 | $19.00 |
| 52-week low | $2.05 | $0.43 |
| Distance from 52-week high | -95.41% | -96.68% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | — | +4304.06% |
| Average volume | 201.35K | 804.18K |
| Shares outstanding | 3.00M | 9.78M |
| Employees | 809 | 28 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ARAY has outperformed CNSY by 192.9 percentage points over the past year.
- Accuray is more profitable, keeping -12.2 cents of every revenue dollar as net income versus -429.4 cents for Cerenome.
About Accuray
ARAY stock →Accuray Incorporated engages in the design, development, and sale of radiosurgery and radiation therapy systems for the treatment of tumors throughout the body in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. The company offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.
Health Care · Medical/Dental Instruments · 809 employees
About Cerenome
CNSY stock →Cerenome, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.
Health Care · Medical/Dental Instruments · 28 employees
ARAY vs CNSY FAQ
Which is bigger, Accuray or Cerenome?
Accuray (ARAY) is larger, with a market capitalization of $6.22M compared with $6.16M for Cerenome (CNSY).
Which stock has performed better over the past year, ARAY or CNSY?
ARAY returned +97.62% over the past 12 months, compared with -95.24% for CNSY (price return, excluding dividends). Past performance does not predict future results.
Are Accuray and Cerenome in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.